Cross-serotypically conserved epitope recommendations for a universal T cell-based dengue vaccine

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Dengue virus (DENV) infection poses a significant global health threat.
• Four co-circulating DENV serotypes complicate vaccine development; prior immunity can enhance disease severity.
• Effective DENV vaccines require strong T cell responses against conserved epitopes across all serotypes.

Purpose of the Study:

• To analyze the cross-serotypic variability of experimentally-determined DENV T cell epitopes.
• To identify DENV epitopes conserved across multiple serotypes for vaccine targeting.
• To assess the potential of conserved epitopes for a universal T cell-based DENV vaccine.

Main Methods:

• Analysis of experimentally-determined DENV T cell epitopes and patient-derived DENV sequences.
• Assessment of epitope conservation patterns across DENV serotypes.
• Evaluation of global human leukocyte antigen (HLA) allele distribution for epitope targeting.

Main Results:

• A near-binary pattern of epitope conservation was observed across DENV serotypes.
• 55 highly conserved DENV epitopes, found in at least 3 serotypes, were identified.
• Conserved epitopes are predominantly located in functionally important regions of DENV non-structural proteins.

Conclusions:

• Highly conserved DENV epitopes offer promising targets for a universal T cell-based vaccine.
• A subset of HLA class I and class II restricted epitopes can potentially cover ~99% of the global population.
• Targeting conserved epitopes can overcome challenges posed by DENV serotype diversity and enhance vaccine efficacy.